{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-007094","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.224541+00:00","generated_at":"2026-05-26T16:33:19.894168+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"PAVmed regains Nasdaq compliance after equity actions; enters 1-year monitoring","bullets":["Notified Feb 14, 2025 that it regained compliance with Nasdaq Listing Rule 5550(b)(1) ($2.5M equity).","Regained compliance via exchange of $22.3M notes for Series C preferred, $2.653M new preferred issuance, and Lucid Diagnostics deconsolidation.","Subject to one-year Mandatory Panel Monitor until Feb 14, 2026; new deficiency could trigger delisting.","Company previously received hearing panel extension to Jan 31, 2025 after failing market value rule."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-007094","json":"https://secwatch.observer/filing/0001493152-25-007094.json","markdown":"https://secwatch.observer/filing/0001493152-25-007094.md","text":"https://secwatch.observer/filing/0001493152-25-007094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315225007094/0001493152-25-007094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315225007094/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T16:33:19.894168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}